Aethlon Medical enters the final week of April with an unusual short-interest pattern at its centre: bears cut positions in half over the middle of the month, then rebuilt sharply — all while the stock shed nearly 9% on the week.
Short interest has gone through a whipsaw. It collapsed from roughly 3.6% of the free float in early April to around 1.0% on April 10, before doubling back to approximately 1.9% by April 28. On a weekly basis that is a 52% jump. The shares themselves closed at $2.15 on April 28, down from $2.35 a week earlier. The two moves — bears returning while the stock falls — point to renewed conviction on the short side following an earlier cover.
The lending market tells a different story from the short-interest rebuild. Borrow availability is quite loose: with the borrow availability running well above what shorting pressure would consume, the infrastructure for a larger short build is clearly in place. Cost to borrow has eased considerably from its March highs — it peaked near 15% in mid-March and has since drifted down to roughly 5.4%, close to its lowest level in six weeks. That decline in borrow cost, alongside ample availability, means the recent short rebuild is not yet straining the lending pool. The ORTEX short score of 32.4 and the days-to-cover rank in the 85th percentile are worth noting — DTC is elevated relative to peers, suggesting that even a modest squeeze in liquidity could make covering difficult.
The fundamental picture remains deeply speculative. The Hemopurifier, Aethlon's extracorporeal device targeting oncology and infectious disease, cleared a meaningful milestone on April 4 when its Data Safety Monitoring Board cleared the Australian oncology trial to advance to Cohort 3. That is a genuine clinical step, but the bear case is well-founded: the company reported a net loss of $1.8 million in the most recent quarter, carries a negative enterprise value, and relies on continued external funding to sustain operations. HC Wainwright initiated coverage back in July 2025 with a Neutral rating and a $1.50 price target — the analyst data here is stale and should not be read as current Street conviction. Geode Capital Management added to a small position as recently as late February, but institutional ownership across the top ten holders totals less than 10% of shares, and the book is thin.
Director-level selling has been a consistent thread. Three board members — Broenniman, Gikakis, and Shah — each executed small sales at the end of March at $2.19 per share. The same three did the same at the end of December and September. The trades are tiny in dollar terms (under $500 each at the March print), scored at minimum significance, and look more like routine compensation-related disposals than directional bets. They are not the story here.
The next scheduled earnings event is June 26. The two most recent prior prints each produced negative next-day reactions: -6.2% in February and -3.8% in mid-February. That consistent post-earnings softness gives the short rebuild some historical grounding — bears appear to be positioning well ahead of the summer print. The key question for the weeks ahead is whether Cohort 3 data from the Australian trial produces any clinical news that shifts the fundamental narrative before that date.
See the live data behind this article on ORTEX.
Open AEMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
